Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 23, 2009, Pages 7964-7970

  Kajiwara, Kazumi ^a,b   Watanabe, Kentaro ^a   Tokiwa, Rei ^a,b   Kurose, Tomoko ^a,b   Ohno, Hiroaki ^a   Tsutsumi, Hiroko ^c   Hata, Yoji ^c   Izumi, Kazuki ^a   Kodama, Eiichi ^a   Matsuoka, Masao ^a   Oishi, Shinya ^a   Fujii, Nobutaka ^a  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c Gekkeikan Sake Company Ltd   (Japan)

Author keywords

Anti HIV peptide; Fusion inhibitor; HIV; Pyroglutamate

Indexed keywords

LACTONE DERIVATIVE; PROTEIN SC35EK; PYROGLUTAMIC ACID DERIVATIVE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL REACTION; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PROTEIN SYNTHESIS;

4-BUTYROLACTONE; ANIMALS; CELL PROLIFERATION; CIRCULAR DICHROISM; HELA CELLS; HIV FUSION INHIBITORS; HIV-1; HUMANS; MICE; PYRROLIDONECARBOXYLIC ACID; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 72149087467     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.10.017     Document Type: Article

References (34)

1. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., and Bozzette S.A. AIDS 18 (2004) 1393
2. For a review, see:. Flexner C. Nat. Rev. Drug Disc. 6 (2007) 959
3. Chan D.C., and Kim P.S. Cell 93 (1998) 981
4. Eckert D.M., and Kim P.S. Annu. Rev. Biochem. 70 (2001) 777
5. Wild C., Oas T., McDanal C., Bolognesi D., and Matthews T. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10537
6. Wild C., Greenwell T., and Matthews T. AIDS Res. Hum. Retroviruses 9 (1993) 1051
7. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., and Matthews T.J. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 9770
8. For a review, see:. Matthews T., Salgo M., Greenberg M., Chung J., DeMasi R., and Bolognesi D. Nat. Rev. Drug Disc. 3 (2004) 215
9. Izumi K., Kodama E., Shimura K., Sakagami Y., Watanabe K., Ito S., Watabe T., Terakawa Y., Nishikawa H., Sarafianos S.G., Kitaura K., Oishi S., Fujii N., and Matsuoka M. J. Biol. Chem. 284 (2009) 4914
10. Watabe T., Terakawa Y., Watanabe K., Ohno H., Nakano H., Nakatsu T., Kato H., Izumi K., Kodama E., Matsuoka M., Kitaura K., Oishi S., and Fujii N. J. Mol. Biol. 392 (2009) 657
11. Otaka A., Nakamura M., Nameki D., Kodama E., Uchiyama S., Nakamura S., Nakano H., Tamamura H., Kobayashi Y., Matsuoka M., and Fujii N. Angew. Chem., Int. Ed. 41 (2002) 2937
12. Oishi S., Ito S., Nishikawa H., Watanabe K., Tanaka M., Ohno H., Izumi K., Sakagami Y., Kodama E., Matsuoka M., and Fujii N. J. Med. Chem. 51 (2008) 388
13. Nishikawa H., Oishi S., Fujita M., Watanabe K., Tokiwa R., Ohno H., Kodama E., Izumi K., Kajiwara K., Naitoh T., Matsuoka M., Otaka A., and Fujii N. Bioorg. Med. Chem. 16 (2008) 9184
14. Nishikawa H., Nakamura S., Kodama E., Ito S., Kajiwara K., Izumi K., Sakagami Y., Oishi S., Ohkubo T., Kobayashi Y., Otaka A., Fujii N., and Matsuoka M. Int. J. Biochem. Cell Biol. 41 (2009) 891
15. Naito T., Izumi K., Kodama E., Sakagami Y., Kajiwara K., Nishikawa H., Watanabe K., Sarafianos S.G., Oishi S., Fujii N., and Matsuoka M. Antimicrob. Agents Chemother. 53 (2009) 1013
16. Bray B.L. Nat. Rev. Drug Disc. 2 (2003) 587
17. Dingermann T. Biotechnol. J. 3 (2008) 90
18. Rao X.C., Li S., Hu J.C., Jin X.L., Hu X.M., Huang J.J., Chen Z.J., Zhu J.M., and Hu F.Q. Protein Expr. Purif. 36 (2004) 11
19. Park T.J., Kim J.S., Choi S.S., and Kim Y. Protein Expr. Purif. 65 (2009) 23
20. Zorko M., Japelj B., Hafner-Bratkovic I., and Jerala R. Biochim. Biophys. Acta 1788 (2009) 314
21. Zhao D.X., Ding Z.C., Liu Y.Q., and Huang Z.X. Protein Expr. Purif. 53 (2007) 232
22. Chang S.G., Kim D.Y., Choi K.D., Shin J.M., and Shin H.C. Biochem. J. 329 (1998) 631
23. Riley J.M., Aggeli A., Koopmans R.J., and McPherson M.J. Biotechnol. Bioeng. 103 (2009) 241
24. Gross E., and Witkop B. J. Biol. Chem. 237 (1962) 1856
25. Kaiser R., and Metzka L. Anal. Biochem. 266 (1999) 1
26. Abraham G.N., and Podell D.N. Mol. Cell. Biochem. 38 (1981) 181
27. Schilling S., Hoffmann T., Rosche F., Manhart S., Wasternack C., and Demuth H.U. Biochemistry 41 (2002) 10849
28. Fernández G.A., Butz P., Trierweiler B., Zöller H., Stärke J., Pfaff E., and Tauscher B. J. Agric. Food Chem. 51 (2003) 8093
29. Chelius D., Jing K., Lueras A., Rehder D.S., Dillon T.M., Vizel A., Rajan R.S., Li T., Treuheit M.J., and Bondarenko P.V. Anal. Chem. 78 (2006) 2370
30. Recently, we have reported the preparation of HIV fusion inhibitor SC34EK by an alternative cleavage reaction using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for the Cys residues:. Tanaka M., Kajiwara K., Tokiwa R., Watanabe K., Ohno H., Tsutsumi H., Hata Y., Izumi K., Kodama E., Matsuoka M., Oishi S., and Fujii N. Bioorg. Med. Chem. 17 (2009) 7487
31. Non-end capped peptide 9 can be obtained by standard recombinant expression in prokaryotes. Peptide 9 for this experiment was obtained by the chemical synthesis.
32. 15 The ring-opened product may be degraded from the C-terminus by endopeptidases in serum.
33. Maeda Y., Venzon D.J., and Mitsuya H. J. Infect. Dis. 177 (1998) 1207
34. Kodama E.I., Kohgo S., Kitano K., Machida H., Gatanaga H., Shigeta S., Matsuoka M., Ohrui H., and Mitsuya H. Antimicrob. Agents Chemother. 45 (2001) 1539